Skip to main content

Advertisement

Log in

Pegfilgrastim overdose: case report and review of the literature

  • Original paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Single-dose pegfilgrastim is commonly used for the prophylaxis of neutropenia in patients receiving myelotoxic chemotherapy. We report a case of a 69-year-old man who was treated with chemotherapy for small-cell lung cancer and mistakenly self-administered a 36 mg overdose of pegfilgrastim, a sixfold increase over the scheduled dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Curran MP, Goa KL. Pegfilgrastim. Drugs. 2002;62:1207–13.

    Article  PubMed  CAS  Google Scholar 

  2. Martinez C, et al. Efficacy and toxicity of high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 1999;24:1273–8.

    Article  PubMed  CAS  Google Scholar 

  3. Pitini V, et al. Spontaneous rupture of spleen during peripheral stem-cell mobilization in a patient with breast cancer. Haematologica. 2000;85:559–60.

    PubMed  CAS  Google Scholar 

  4. Becker PS, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–9.

    PubMed  CAS  Google Scholar 

  5. Donadieu J, Beaupain B, Rety-Jacob F, Nove-Josserand R. Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica. 2009;94:1175–7.

    Article  PubMed  CAS  Google Scholar 

  6. Draper BK, Robbins JB, Stricklin GP. Bullous Sweet’s syndrome in congenital neutropenia: association with pegfilgrastim. J Am Acad Dermatol. 2005;52:901–5.

    Article  PubMed  Google Scholar 

  7. Schilero GJ, Oropello J, Benjamin E. Impairment in gas exchange after granulocyte colony stimulating factor (GCSF) in a patient with the adult respiratory distress syndrome. Chest. 1995;107:276–8.

    Article  PubMed  CAS  Google Scholar 

  8. Dufour C, et al. Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. Haematologica. 2010;95:684–5.

    Article  PubMed  Google Scholar 

  9. Burstein HJ, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–7.

    Article  PubMed  CAS  Google Scholar 

  10. Ishiguro H, et al. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim. Ann Oncol. 2008;19:1019–20.

    Article  PubMed  CAS  Google Scholar 

  11. Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24:2392–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nissim Haim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaidar–Person, O., Moskovitz, M., Charas, T. et al. Pegfilgrastim overdose: case report and review of the literature. Med Oncol 28 (Suppl 1), 697–698 (2011). https://doi.org/10.1007/s12032-010-9751-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9751-5

Keywords

Navigation